Agents for alleviating symptoms accompanied by inflammation

Details Agents for alleviating symptoms accompanied by inflammation Agents for alleviating symptoms accompanied by inflammation

2008-01-29

2008-01-29

Weber, Jon (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S382000, C530S383000, C530S385000

Reexamination Certificate

active

07323442

ABSTRACT:
The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.

REFERENCES:
patent: 5240909 (1993-08-01), Nitsche
patent: 2006/0039921 (2006-02-01), MacDonald et al.
patent: 0 584 558 (1994-03-01), None
patent: 8-165248 (1996-06-01), None
patent: 10-114675 (1998-05-01), None
Elass-Rochard et al., Infection and Immunity, vol. 66, No. 2, pp. 486-491, Feb. 1998.
Martins et al., Clinical and Diagnostic Laboratory Immunology, vol. 2, No. 6, pp. 763-765, Nov. 1995.
Patent Abstracts of Japan, JP 51-78759, Jul. 20, 1993.
Patent Abstracts of Europe, EP 0 579 830, Jan. 26, 1994.
Patent Abstracts of Japan, JP 7-300425, Nov. 14, 1995.
Patent Abstracts of Japan, JP 10-114675, May 6, 1998.
Patent Abstracts of Japan, JP 10-245347, Sep. 14, 1998.
Patent Abstracts of Japan, JP 11-029600, Feb. 2, 1999.
Patent Abstracts of Japan, JP 2000-229881, Aug. 22, 2000.
E. Elass-Rochard, et al., Infection and Immunity, vol. 66, No. 2, pp. 486-491, “Lactoferrin Inhibits the Endotoxin Interaction With CD14 by Competition With the Lipopolysaccharide-Binding Protein”, Feb. 1998.
D. Jean, et al., American Journal of Respiratory and Critical Care Medicine, vol. 158, pp. 1702-1708, “Protective Effect of Endotoxin Instillation on Subsequent Bacteria-Induced Acute Lung Injury in Rats”, 1998.
M. Machnicki, et al., Int. J. Exp. Path., vol. 74, pp. 433-439, “Lactoferrin Regulates the Release of Tumour Necrosis Factor Alpha and Interleukin 6 in Vivo”, 1993.
O. Levy, Antimicrobial Agents and Chemotherapy, vol. 44, No. 11, pp. 2925-2931, “A Neutrophil-Derived Anti-Infective Molecule: Bactericidal/Permeability-Increasing Protein”, Nov. 2000.
M. Yajima, et al., FASEB Journal, vol. 13, No. 4, A591 (1999).
M. Yajima, et al., The 4thInternational Conference on Lactoferrin, Program & Abstract, pp. 77 (1999).
5thInternational Conference on Lactoferrin: Structure, Function and Applications, May 4-9, 2001, Banff, Alberta Canada.

Affiliated with

Also associated with

Rating

Agents for alleviating symptoms accompanied by inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agents for alleviating symptoms accompanied by inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents for alleviating symptoms accompanied by inflammation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2778523